Latest News
KKR has sold Capsugel to Lonza for USD5.5 billion. As part of the sale, approximately USD35 million of proceeds were distributed to non-management level employees of the company, including all colleagues from the company’s thirteen manufacturing facilities around the world.
All Capsugel employees globally participated in the distribution of proceeds from the sale.
“Capsugel was a terrific outcome, not only in terms of the financial results for our fund investors, but also in the way we and the management team and all of the company’s employees partnered together to really drive a transformation of the company,” says Pete Stavros,
LDC-backed Fishawack Group of Companies, a specialist provider of scientific communications services to global pharmaceutical companies, has acquired the US-based Carling Group of Companies. The transaction value has not been disclosed.
The Group includes Carling Communications, a full-service healthcare marketing and communications agency, and MCME Global, the specialist provider of medical education services. Both businesses are headquartered in San Diego.
Founded in 2010 by Didi Discar, and with offices in San Diego and London, Carling has a team of more than 100 people specialising in full-service marketing, advertising and physician communications. It supports clients across the pharmaceutical, biotechnology and
Moelis & Company, an independent investment bank, has apointed Pablo de la Infiesta as a Managing Director and Head of the Private Funds Advisory (PFA) group in EMEA.
He will join the Firm’s London office in October and will provide capital raising, secondary and other advisory services to private fund sponsors and limited partners globally.
De la Infiesta has over 20 years of private equity fund placement, secondary advisory, and investment banking experience. He joins Moelis & Company after 11 years at Lazard where he was most recently a Managing Director and European Head of the Private Capital Advisory
Middle market private equity firm Stellex Capital Management (Stellex) has held the closing of its debut fund, Stellex Capital Partners (the Fund), with aggregate commitments of USD870 million, exceeding the Fund’s USD750 million target.
Stellex has a flexible investment strategy that executes deep value control-oriented middle market investments through structured private equity buyouts or purchases of secondary market debt. Stellex’s target investment size is USD25 million to USD100 million, with additional capacity as needed. Stellex primarily focuses on manufacturing and service businesses within sectors such as automotive, aerospace, building products, defense, industrial equipment, metal fabrication and transportation.
To date,
MidOcean Credit Partners, an affiliate of MidOcean Partners, a premier New York-based alternative asset manager, has closed a USD600 million collateralised loan obligation (CLO), MidOcean Credit CLO VII.
The transaction was led by Goldman Sachs & Co.
The CLO will be backed by a portfolio of primarily senior-secured leveraged loans and will have a four-year reinvestment period and a two-year non-call period. The transaction is MidOcean’s first CLO structured to comply with US risk-retention rules.
Jim Wiant (pictured), Managing Director at MidOcean Credit Partners, says: “The successful closing of CLO VII, MidOcean’s largest CLO to date, demonstrates our
The Luxembourg Stock Exchange (LuxSE) has listed the first ever Reserved Alternative Investment Fund (RAIF). The new RAIF was brought to market by Finexis and has been listed on the Euro MTF market.
RAIFs are a new type of vehicle that combine the characteristics and structures of specialised investment funds (SIFs) and investment companies in risk capital (SICARs) qualifying as Alternative Investment Funds (AIFs). However, unlike traditional AIFs, RAIFs are not subject to approval from Luxembourg’s regulator, the Commission de Surveillance du Secteur Financier, also known as the CSSF.
The Law of 23 July 2016, which came into effect
The London Stock Exchange has seen nine fund IPOs on its markets to date in 2017, raising GBP1.4 billion. London listed funds have also raised GBP3.6 billion in further capital in the first half of the year.
London continues to be an attractive market for international fund managers, particularly from the United States. Since the start of the year, US fund managers have listed funds worth over GBP3.5 billion in London.
Most notable is the increasingly diversified nature of the funds, from microcap, supporting SMEs, and real estate specific funds for social housing, private rented sector and
AxiomSL, a provider of risk data management and regulatory reporting technology for the financial services industry, has secured a strategic investment from growth equity firm TCV.
This investment represents AxiomSL’s first institutional financing, having bootstrapped to scale since its founding in 1991. TCV’s investment will enable the company to accelerate growth and cement its position as the financial industry standard for risk and regulatory compliance data management. As part of the investment, the AxiomSL board of directors will benefit from the expertise of Rick Kimball, Founding General Partner at TCV, and Nari Ansari, Principal at TCV.
“We selected TCV
Private equity investment firm HIG Capital (HIG) has sold its portfolio company Comverge through the sale of its parent company, Peak Holding Corp, to Itron in a cash transaction valued at approximately USD100 million.
Comverge is a leading provider of demand response, energy efficiency, customer engagement and distributed generation solutions to utility customers. Leveraging a broad suite of demand management products, Comverge provides all of the products and services needed to operate a demand response program, allowing utilities to better manage energy load and helping customers consume energy more efficiently.
Through the acquisition of Comverge in May 2012, HIG
An affiliate of HIG Europe (HIG) has acquired a controlling stake in Santa Lucia Pharma Apps (SLPA), an Italian provider of advanced services to hospitals.
SLPA offers integrated turn-key solutions to hospitals for the traceability and management of unit dose drugs and medical devices. SLPA solutions, which include proprietary software, patented robotic technologies and specialist support services, enable drugs and medical devices management from digital prescription to automated personalised unit dose treatment, up to software controlled administration to patients. Complete traceability of medications and medical devices allows significant reduction in errors in therapy management and in related waste, resulting in
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
